FluoSphera has developed in vitro human biosystems that mimic essential features of human body organization.
FluoSphera's biosystems generate data that predict much better the effects of drugs on patients, thus reducing the costs of drug development failure up to several hundreds of million dollars per drug.
Using this technology, FluoSphera proposes R&D services to pharmaceutical companies willing to de-risk drug development projects.
Drug profiling with our biosystems allows the discovery of more efficient drugs for the patients, with less adverse side effects, and it contributes to reduce animal experimentation.
FluoSphera's biosystems generate data that predict much better the effects of drugs on patients, thus reducing the costs of drug development failure up to several hundreds of million dollars per drug.
Using this technology, FluoSphera proposes R&D services to pharmaceutical companies willing to de-risk drug development projects.
Drug profiling with our biosystems allows the discovery of more efficient drugs for the patients, with less adverse side effects, and it contributes to reduce animal experimentation.
Location: Switzerland
Total raised: $3.71M
Investors 3
| Date | Name | Website |
| 09.11.2021 | Venture Ki... | venturekic... |
| - | EFI Lake G... | lakegeneva... |
| 07.07.2023 | Mountain L... | mountainla... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 13.01.2026 | - | $1.44M | Soulmates ... |
| 25.01.2024 | Grant | $1.27M | - |
| 01.03.2023 | Pre-Seed | $1M | IndieBio |
Mentions in press and media 26
| Date | Title | Description |
| 02.09.2026 | FluoSphera powers ahead with Debiopharm and Leica Microsystems | The new offering is designed to support the characterization of antibody-drug conjugates (ADCs), bispecific antibodies, therapeutic antibodies and other antibody-based modalities. Antibody candidates can be labeled using AbYlink™ and subse... |
| 16.03.2026 | Ternary Therapeutics targets “undruggable” proteins with AI-designed molecular glues, raising €4.1 million | London-based BioTech startup Ternary Therapeutics has raised €4.1 million (£3.6 million) in Seed funding to scale an AI platform designed to create a new class of medicines known as molecular glues. The round was led by European venture fir... |
| 20.01.2026 | Soulmates Ventures Backs FluoSphera Rethinking Preclinical Drug Development | With Soulmates Ventures’ support, Fluosphera is building scalable, human-relevant preclinical models to reduce drug development failure Its multiplexed platform enables early, decision-grade insights across multiple interacting human tissue... |
| 13.01.2026 | Orca Bio Secures $250M for Cell Therapy Launch and Pipeline Expansion | Orca Bio, a leader in cell therapy, recently raised $250 million. This significant capital influx ensures commercial readiness for Orca-T, its lead allogeneic T-cell immunotherapy. An FDA Prescription Drug User Fee Act (PDUFA) target action... |
| 13.01.2026 | FluoSphera Secures €1.23M to Revolutionize Drug Discovery with Human-Relevant Platform | FluoSphera, a Swiss biotech firm, secured €1.23 million. This vital funding propels its advanced drug discovery platform. The patented multi-tissue system offers animal-free, human-relevant testing. It predicts drug effects with high accura... |
| 13.01.2026 | FluoSphera raises CHF 1.15M to scale human-based preclinical platform | Drug development remains costly and inefficient, with over 90% of candidates failing in clinical trials due largely to the limits of traditional preclinical models. Conventional cell cultures and animal testing often fail to predict how com... |
| 12.01.2026 | Marvell to Acquire XConn Technologies | Marvell Technology, Inc. (NASDAQ: MRVL), a Santa Clara, CA-based company which specializes in data infrastructure semiconductor solutions, acquired XConn Technologies, a San Jose, CA-based hybrid switch company supporting both CXL and PCIe ... |
| 12.01.2026 | FluoSphera Raises CHF 1.15M to Scale Human-Based Preclinical Platform | Developing a new drug takes on average 10 to 15 years, and costs between $2 and $3 billion, according to Deloitte’s 2023 Pharmaceutical Innovation Report. Yet, despite these investments, over 90% of drug candidates still fail in clinical t... |
| 12.01.2026 | Orca Bio Raises $250M in Aggregate Funding | Orca Bio, a Menlo Park, CA-based late-stage biotechnology company developing cell therapies, raised $250M in aggregate funding. The amount consisted of $250M in new equity capital including a Series F led by Lightspeed Venture Partners from... |
| 12.01.2026 | FluoSphera secures €1.23M to expand human-based preclinical platform | FluoSphera, a Swiss biotech startup focused on drug safety and efficacy testing, has raised €1.23 million (CHF1.15 million) in funding. The round was led by Soulmates Ventures and a Swiss business angel, with participation from IndieBio New... |
Show more